Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Pertussis in adolescents and its prevention using Tdap vaccination.

Mink CM, Yeh SH.

Adolesc Med State Art Rev. 2010 Aug;21(2):220-35, viii. Review.

PMID:
21047026
2.

Infections in child-care facilities and schools.

Mink CM, Yeh S.

Pediatr Rev. 2009 Jul;30(7):259-69. doi: 10.1542/pir.30-7-259. Review. No abstract available.

PMID:
19570924
3.

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

Tondella ML, Carlone GM, Messonnier N, Quinn CP, Meade BD, Burns DL, Cherry JD, Guiso N, Hewlett EL, Edwards KM, Xing D, Giammanco A, Wirsing von K├Ânig CH, Han L, Hueston L, Robbins JB, Powell M, Mink CM, Poolman JT, Hildreth SW, Lynn F, Morris A.

Vaccine. 2009 Feb 5;27(6):803-14. doi: 10.1016/j.vaccine.2008.11.072. Epub 2008 Dec 9.

PMID:
19071179
5.

Introduction of tetanus toxoid and reduced diphtheria toxoid vaccines in the United States.

Mink CM.

Pediatr Infect Dis J. 2006 Apr;25(4):363-4. No abstract available.

PMID:
16567991
6.

Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.

Lottenbach KR, Granoff DM, Barenkamp SJ, Powers DC, Kennedy D, Irby-Moore S, Homan SM, Mink CM.

J Am Geriatr Soc. 2004 Nov;52(11):1883-7.

PMID:
15507066
7.

Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination.

Lottenbach KR, Mink CM, Barenkamp SJ, Anderson EL, Homan SM, Powers DC.

Infect Immun. 1999 Sep;67(9):4935-8.

8.

A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.

Keitel WA, Muenz LR, Decker MD, Englund JA, Mink CM, Blumberg DA, Edwards KM.

J Infect Dis. 1999 Aug;180(2):397-403.

PMID:
10395855
9.

Characterization of human bactericidal antibodies to Bordetella pertussis.

Weiss AA, Mobberley PS, Fernandez RC, Mink CM.

Infect Immun. 1999 Mar;67(3):1424-31.

10.

Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults.

Powers DC, Anderson EL, Lottenbach K, Mink CM.

J Infect Dis. 1996 Apr;173(4):1014-8.

PMID:
8603942
11.

Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.

Meade BD, Lynn F, Reed GF, Mink CM, Romani TA, Deforest A, Deloria MA.

Pediatrics. 1995 Sep;96(3 Pt 2):595-600. Erratum in: Pediatrics 1995 Dec;96(6):following 1199.

PMID:
7659484
12.

Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakeh H, Pais L, Holder P, Carlone GM.

Infect Immun. 1994 Aug;62(8):3391-5.

13.
14.

Acellular pertussis vaccines in infants: evaluation of single component and two-component products.

Anderson EL, Mink CM, Berlin BS, Shih CN, Tung FF, Belshe RB.

Vaccine. 1994 Jan;12(1):28-31.

PMID:
8303937
15.

Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants.

Mulholland EK, Ahonkhai VI, Greenwood AM, Jonas LC, Lukacs LJ, Mink CM, Staub JM, Todd J, Vella PP, Greenwood BM.

Pediatr Infect Dis J. 1993 Aug;12(8):632-7.

PMID:
8414774
16.
17.

Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide.

Lucas AH, Azmi FH, Mink CM, Granoff DM.

J Immunol. 1993 Mar 1;150(5):2056-61.

PMID:
8436834
18.

A search for Bordetella pertussis infection in university students.

Mink CM, Cherry JD, Christenson P, Lewis K, Pineda E, Shlian D, Dawson JA, Blumberg DA.

Clin Infect Dis. 1992 Feb;14(2):464-71.

PMID:
1554832
19.

Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group.

Blumberg DA, Mink CM, Cherry JD, Johnson C, Garber R, Plotkin SA, Watson B, Ballanco GA, Daum RS, Sullivan B, et al.

J Pediatr. 1991 Aug;119(2):194-204.

PMID:
1907317
20.

Pathophysiology of reactions associated with pertussis vaccine.

Blumberg DA, Mink CM, Lewis K, Chatfield P, Leach C, Smith LP, Christenson PD, Guravitz L, Steinfeld MB, Marcy SM, et al.

Dev Biol Stand. 1991;73:289-95.

PMID:
1778321
21.

Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.

Blumberg DA, Mink CM, Cherry JD, Reisinger KS, Blatter MM, Congeni BL, Dekker CL, Stout MG, Mezzatesta JR, Scott JV, et al.

J Pediatr. 1990 Jul;117(1 Pt 1):46-51.

PMID:
2196360
22.

Metabolic and hematologic effects and immune complex formation related to pertussis immunization.

Mink CM, Uhari M, Blumberg DA, Knip M, Lewis K, Christenson PD, Toyoda M, Jordan SC, Levin SR, Cherry JD.

Pediatr Res. 1990 Apr;27(4 Pt 1):353-7.

PMID:
2188202

Supplemental Content

Support Center